Angiotensin antagonism and antihypertensive activity of phosphodiesterase inhibiting agents.
D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D000818:Animals; D001626:Bethanechol Compounds / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D001920:Bradykinin / Q000494:pharmacology; D001949:Bretylium Compounds / Q000494:pharmacology; D003647:Debrisoquin / Q000494:pharmacology; D003981:Diazoxide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006145:Guanethidine / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors*; D010643:Phenoxybenzamine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors; D051381:Rats; D013806:Theophylline / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology*
D001626:Bethanechol Compounds; D001949:Bretylium Compounds; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents; D010643:Phenoxybenzamine; D000804:Angiotensin II; D006830:Hydralazine; D013806:Theophylline; D003981:Diazoxide; D001920:Bradykinin; D003647:Debrisoquin; D009638:Norepinephrine; D010646:Phentolamine; D006145:Guanethidine